Crypto Briefing September 07, 2026

Insilico Medicine’s rentosertib shows potential to slow aging in landmark Phase III trial

Insilico Medicine’s rentosertib shows potential to slow aging in landmark Phase III trial

Rentosertib's success could revolutionize aging treatment, influencing therapies for numerous age-related diseases beyond lung conditions.

The post Insilico Medicine’s rentosertib shows potential to slow aging in landmark Phase III trial appeared first on Crypto Briefing.

You might also like

Ethereum mainnet averages record 2.16M daily tran…
Nov 09, 2026 Read
Nvidia shares set to drop 5% amid CEO investigati…
Nov 09, 2026 Read
Telegram sees over 700,000 self-custodial wallets…
Nov 09, 2026 Read
Core Scientific projects $1.8 billion annual run-…
Nov 09, 2026 Read